Kymera Therapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. (ticker: KYMR) is a US-listed clinical-stage biotechnology company traded on NASDAQ in the United States. Headquartered in Watertown, Massachusetts, the company is focused on reinventing the treatment of serious diseases through targeted protein degradation (TPD), a drug-discovery approach designed to selectively eliminate disease-causing proteins that have historically been difficult to address with conventional medicines. Kymera’s corporate identity and scientific strategy were built around this modality, and management emphasizes a discovery engine capable of advancing at least one new program into clinical testing each year. ([kymeratx.com](https://www.kymeratx.com/about-us/our-company/)) Kymera’s core business is the development of highly differentiated, first-in-class small-molecule degraders, with a primary focus on immunology and inflammatory disease. The company is trying to translate the promise of protein degradation into oral therapies that could offer a convenient and potentially more effective alternative to injectable biologics or older mechanisms of action. Its most advanced program is KT-621, an oral STAT6 degrader that is currently in Phase 2 testing in atopic dermatitis and asthma. Kymera also advanced KT-579, an oral IRF5 degrader, into first-in-human Phase 1 studies in 2026. In addition, the company continues to work through collaborative programs, including an IRAK4 collaboration with Sanofi, which prioritized KT-485 for future development. ([investors.kymeratx.com](https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025/)) From a competitive standpoint, Kymera occupies an innovative niche within the biotech sector, where scientific differentiation, clinical execution, and data quality are critical to long-term value creation. The company positions itself as a pioneer in bringing oral degraders beyond oncology into immunology, and it notes that it advanced the first oral small-molecule degrader for immunological diseases into clinical testing. That first-mover profile is important because TPD remains a relatively new therapeutic category, and Kymera is attempting to establish itself as one of the category leaders in inflammation and immune-mediated diseases. ([kymeratx.com](https://www.kymeratx.com/about-us/our-company/)) Kymera’s geographic base is in the United States, with its operating footprint centered in the Boston biotech ecosystem, but its clinical programs are designed for global development. Recent highlights include positive Phase 1b data for KT-621 reported in December 2025, FDA Fast Track designation for KT-621, expansion of the BROADEN2 Phase 2b trial to adolescents in January 2026, and initiation of the BREADTH Phase 2b asthma study in January 2026. On the financing side, the company strengthened its balance sheet in 2025 through an equity offering and partnership-related cash inflows, extending its cash runway into the second half of 2028 according to management. ([investors.kymeratx.com](https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-fourth-quarter-and-full-year-2025/))